Immunomodulation by AZD1656 reverses cardiac dysfunction, metabolic remodelling and reduces infarct size in type 2 diabetic cardiomyopathy.

ABSTRACT: Type 2 Diabetes (T2D) can lead to diabetic cardiomyopathy (dbCM), which is characterised by chronic, systemic inflammation, disrupted metabolism and impaired cardiac function. However, whether cardiac inflammation is present in dbCM and causally linked to metabolic remodelling remains unknown. AZD1656 (AZD), an activator of glucokinase, was postulated to provide glycaemic control in T2D by acting on in the pancreas and liver. However, AZD failed to control hyperglycaemia in clinical trials. Nevertheless, testing of the drug in COVID-19 T2D patients as part of the ARCADIA trial indicated an immunomodulatory effect. Therefore, we used the db/db mouse model of dbCM and an integrated in vivo and ex vivo experimental approach to examine the effects of AZD on cardiac functional and metabolic dis

SUBMITTER: Anderson S 

PROVIDER: S-EPMC12027331 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature